Marianna Graziosi , Julia S. Rohde , Praachi Tiwari , Jedidiah Siev , David B. Yaden
{"title":"迷幻剂、强迫症和相关障碍：系统回顾","authors":"Marianna Graziosi , Julia S. Rohde , Praachi Tiwari , Jedidiah Siev , David B. Yaden","doi":"10.1016/j.jocrd.2024.100873","DOIUrl":null,"url":null,"abstract":"<div><p>This systematic review analyzes the current literature on the potential therapeutic use of classic psychedelics (i.e., psilocybin, lysergic acid diethylamide [LSD], N,N-dimethyltryptamine [DMT], 5-methoxy-N,N-dimethyltryptamine [5-MeO-DMT], mescaline, and other classic psychedelic analogs utilized in preclinical models) in obsessive-compulsive disorder (OCD) and related disorders. Our search identified 23 articles meeting our predetermined eligibility criteria, comprising 2 non-systematic reviews, 11 preclinical studies investigating the use of classic psychedelics or analogs in preclinical models of OCD, 8 case studies or case reports, and 2 clinical trials. This review provides an up-to-date synthesis of psychedelic OCD research, bridging preclinical findings, historical case reports, and initial clinical trial outcomes. Psilocybin appears to be the most widely used classic psychedelic and is well-tolerated in both OCD and body dysmorphic disorder (BDD) populations, with some participants experiencing significant symptom reduction. This review contributes to our understanding of the potential of classic psychedelics (in particular LSD and psilocybin) as novel therapeutic interventions for OCD and related disorders, offering insights into future research directions and clinical applications in this emerging field.</p></div>","PeriodicalId":48902,"journal":{"name":"Journal of Obsessive-Compulsive and Related Disorders","volume":"41 ","pages":"Article 100873"},"PeriodicalIF":1.9000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Psychedelics, OCD and related disorders: A systematic review\",\"authors\":\"Marianna Graziosi , Julia S. Rohde , Praachi Tiwari , Jedidiah Siev , David B. Yaden\",\"doi\":\"10.1016/j.jocrd.2024.100873\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>This systematic review analyzes the current literature on the potential therapeutic use of classic psychedelics (i.e., psilocybin, lysergic acid diethylamide [LSD], N,N-dimethyltryptamine [DMT], 5-methoxy-N,N-dimethyltryptamine [5-MeO-DMT], mescaline, and other classic psychedelic analogs utilized in preclinical models) in obsessive-compulsive disorder (OCD) and related disorders. Our search identified 23 articles meeting our predetermined eligibility criteria, comprising 2 non-systematic reviews, 11 preclinical studies investigating the use of classic psychedelics or analogs in preclinical models of OCD, 8 case studies or case reports, and 2 clinical trials. This review provides an up-to-date synthesis of psychedelic OCD research, bridging preclinical findings, historical case reports, and initial clinical trial outcomes. Psilocybin appears to be the most widely used classic psychedelic and is well-tolerated in both OCD and body dysmorphic disorder (BDD) populations, with some participants experiencing significant symptom reduction. This review contributes to our understanding of the potential of classic psychedelics (in particular LSD and psilocybin) as novel therapeutic interventions for OCD and related disorders, offering insights into future research directions and clinical applications in this emerging field.</p></div>\",\"PeriodicalId\":48902,\"journal\":{\"name\":\"Journal of Obsessive-Compulsive and Related Disorders\",\"volume\":\"41 \",\"pages\":\"Article 100873\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Obsessive-Compulsive and Related Disorders\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2211364924000174\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Obsessive-Compulsive and Related Disorders","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2211364924000174","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PSYCHIATRY","Score":null,"Total":0}
Psychedelics, OCD and related disorders: A systematic review
This systematic review analyzes the current literature on the potential therapeutic use of classic psychedelics (i.e., psilocybin, lysergic acid diethylamide [LSD], N,N-dimethyltryptamine [DMT], 5-methoxy-N,N-dimethyltryptamine [5-MeO-DMT], mescaline, and other classic psychedelic analogs utilized in preclinical models) in obsessive-compulsive disorder (OCD) and related disorders. Our search identified 23 articles meeting our predetermined eligibility criteria, comprising 2 non-systematic reviews, 11 preclinical studies investigating the use of classic psychedelics or analogs in preclinical models of OCD, 8 case studies or case reports, and 2 clinical trials. This review provides an up-to-date synthesis of psychedelic OCD research, bridging preclinical findings, historical case reports, and initial clinical trial outcomes. Psilocybin appears to be the most widely used classic psychedelic and is well-tolerated in both OCD and body dysmorphic disorder (BDD) populations, with some participants experiencing significant symptom reduction. This review contributes to our understanding of the potential of classic psychedelics (in particular LSD and psilocybin) as novel therapeutic interventions for OCD and related disorders, offering insights into future research directions and clinical applications in this emerging field.
期刊介绍：
Journal of Obsessive-Compulsive and Related Disorders (JOCRD) is an international journal that publishes high quality research and clinically-oriented articles dealing with all aspects of obsessive-compulsive disorder (OCD) and related conditions (OC spectrum disorders; e.g., trichotillomania, hoarding, body dysmorphic disorder). The journal invites studies of clinical and non-clinical (i.e., student) samples of all age groups from the fields of psychiatry, psychology, neuroscience, and other medical and health sciences. The journal''s broad focus encompasses classification, assessment, psychological and psychiatric treatment, prevention, psychopathology, neurobiology and genetics. Clinical reports (descriptions of innovative treatment methods) and book reviews on all aspects of OCD-related disorders will be considered, as will theoretical and review articles that make valuable contributions.
Suitable topics for manuscripts include:
-The boundaries of OCD and relationships with OC spectrum disorders
-Validation of assessments of obsessive-compulsive and related phenomena
-OCD symptoms in diverse social and cultural contexts
-Studies of neurobiological and genetic factors in OCD and related conditions
-Experimental and descriptive psychopathology and epidemiological studies
-Studies on relationships among cognitive and behavioral variables in OCD and related disorders
-Interpersonal aspects of OCD and related disorders
-Evaluation of psychological and psychiatric treatment and prevention programs, and predictors of outcome.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
